Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 ...

The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in ...

AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in ...

Oct 2 (Reuters) - Summit Therapeutics on Friday announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo ...

Together with its site for genomic medicine at 100 Binney Street, The AstraZeneca R&D Center Kendall Square will be home to nearly 2,000 world-class researchers and scientists who will accelerate the ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

AstraZeneca has completed a $2 billion strategic equity investment in Summit Therapeutics, providing additional capital to accelerate development of ivonescimab across multiple solid tumor indications ...

The European Commission has revoked the EU marketing authorization for Hansoh Pharma’s lung cancer drug Aumseqa (aumolertinib ...

Summit Therapeutics Inc. ( SMMT) on Monday announced the closing of AstraZeneca's ( AZN) $2 billion strategic equity investment, which will support accelerated development of ivonescimab, an ...

Sept 28 (Reuters) - Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the ...